Research analysts at Cantor Fitzgerald assumed coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI) in a research note issued to investors on Thursday, August 23rd, MarketBeat reports. The firm set an “overweight” rating and a $32.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price suggests a potential upside of 44.27% from the company’s previous close.

Several other research analysts have also recently issued reports on ITCI. ValuEngine cut Intra-Cellular Therapies from a “buy” rating to a “hold” rating in a research report on Wednesday, June 27th. BidaskClub cut Intra-Cellular Therapies from a “hold” rating to a “sell” rating in a research report on Friday, June 22nd. Royal Bank of Canada reaffirmed a “buy” rating and set a $35.00 target price on shares of Intra-Cellular Therapies in a research report on Friday, August 3rd. Zacks Investment Research raised Intra-Cellular Therapies from a “sell” rating to a “hold” rating in a research report on Tuesday, May 8th. Finally, Canaccord Genuity set a $31.00 price objective on Intra-Cellular Therapies and gave the stock a “buy” rating in a research report on Wednesday, June 6th. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Intra-Cellular Therapies presently has an average rating of “Buy” and a consensus price target of $28.00.

Shares of NASDAQ ITCI traded up $0.46 during midday trading on Thursday, hitting $22.18. 189,532 shares of the stock traded hands, compared to its average volume of 192,407. Intra-Cellular Therapies has a one year low of $13.93 and a one year high of $25.82.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($0.68) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.76) by $0.08. Intra-Cellular Therapies had a negative return on equity of 31.73% and a negative net margin of 39,745.53%. equities analysts anticipate that Intra-Cellular Therapies will post -3.15 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently modified their holdings of the company. PointState Capital LP bought a new stake in shares of Intra-Cellular Therapies during the 1st quarter valued at $39,334,000. Schroder Investment Management Group bought a new position in Intra-Cellular Therapies in the 2nd quarter worth about $21,222,000. Columbus Circle Investors increased its stake in Intra-Cellular Therapies by 72.2% in the 1st quarter. Columbus Circle Investors now owns 556,156 shares of the biopharmaceutical company’s stock worth $11,707,000 after acquiring an additional 233,107 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Intra-Cellular Therapies by 13.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,356,720 shares of the biopharmaceutical company’s stock worth $23,974,000 after acquiring an additional 159,860 shares during the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. bought a new position in Intra-Cellular Therapies in the 2nd quarter worth about $1,756,000. 71.54% of the stock is currently owned by hedge funds and other institutional investors.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases. The company is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, and other neuropsychiatric and neurological disorders.

Recommended Story: Short Selling

Analyst Recommendations for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.